Clinical proteomics

Clinical proteomics: Insights from IGF-I

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Clinical proteomics : Insights from IGF-I. / Albrethsen, Jakob; Frederiksen, Hanne; Johannsen, Trine Holm; Andersson, Anna-Maria; Juul, Anders.

I: Clinica chimica acta; international journal of clinical chemistry, Bind 477, 2018, s. 18-23.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Albrethsen, J, Frederiksen, H, Johannsen, TH, Andersson, A-M & Juul, A 2018, 'Clinical proteomics: Insights from IGF-I', Clinica chimica acta; international journal of clinical chemistry, bind 477, s. 18-23. https://doi.org/10.1016/j.cca.2017.11.034

APA

Albrethsen, J., Frederiksen, H., Johannsen, T. H., Andersson, A-M., & Juul, A. (2018). Clinical proteomics: Insights from IGF-I. Clinica chimica acta; international journal of clinical chemistry, 477, 18-23. https://doi.org/10.1016/j.cca.2017.11.034

Vancouver

Albrethsen J, Frederiksen H, Johannsen TH, Andersson A-M, Juul A. Clinical proteomics: Insights from IGF-I. Clinica chimica acta; international journal of clinical chemistry. 2018;477:18-23. https://doi.org/10.1016/j.cca.2017.11.034

Author

Albrethsen, Jakob ; Frederiksen, Hanne ; Johannsen, Trine Holm ; Andersson, Anna-Maria ; Juul, Anders. / Clinical proteomics : Insights from IGF-I. I: Clinica chimica acta; international journal of clinical chemistry. 2018 ; Bind 477. s. 18-23.

Bibtex

@article{16ffdf0a7fc745b1bfc41c8bad1a4975,

title = "Clinical proteomics: Insights from IGF-I",

abstract = "Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.",

keywords = "Chromatography, High Pressure Liquid, Humans, Insulin-Like Growth Factor I/analysis, Mass Spectrometry, Protein Isoforms, Proteomics",

author = "Jakob Albrethsen and Hanne Frederiksen and Johannsen, {Trine Holm} and Anna-Maria Andersson and Anders Juul",

year = "2018",

doi = "10.1016/j.cca.2017.11.034",

language = "English",

volume = "477",

pages = "18--23",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Clinical proteomics

T2 - Insights from IGF-I

AU - Albrethsen, Jakob

AU - Frederiksen, Hanne

AU - Johannsen, Trine Holm

AU - Andersson, Anna-Maria

AU - Juul, Anders

PY - 2018

Y1 - 2018

N2 - Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.

AB - Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.

KW - Chromatography, High Pressure Liquid

KW - Humans

KW - Insulin-Like Growth Factor I/analysis

KW - Mass Spectrometry

KW - Protein Isoforms

KW - Proteomics

U2 - 10.1016/j.cca.2017.11.034

DO - 10.1016/j.cca.2017.11.034

M3 - Review

C2 - 29196187

VL - 477

SP - 18

EP - 23

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -

ID: 217615453